Coutu FA, Malaeb D, Iorio OC, et al. Measuring lung mechanics in patients with COPD using the handheld portable rapid expiratory occlusion monitor (REOM): A cross-sectional study. Physiol Rep ...

The approval will change care of patients with COPD who are already maximized on inhaler therapies and continue to have exacerbations, “as this is the only biologic approved for patients with ...

TIRUCHY: From June 4, all 84 primary health centres (PHCs) in the district, including those under the corporation, will launch structured screening for Chronic Obstructive Pulmonary Disease (COPD ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype, according to ...

An experimental COPD medicine from Sanofi and Regeneron Pharmaceuticals produced mixed results in a pair of studies, the companies said Friday, sending both firms’ shares down in early and pre ...

Dr Batra shares tips on how to recognise the difference between a cold and a COPD flare-up: Related stories. Seasonal respiratory viruses: Symptoms, risk factors, and how to prevent viral infections.

Learn about COPD medications, including bronchodilators, steroids, and combination treatments. Understand how they work, their side effects, and ways to manage COPD effectively.

Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures. Skip to main content Tuesday 24 June 2025 ...

GLOUCESTER — In April alone, Leatrice Croswell was hospitalized three times for severe shortness of breath linked to his chronic obstructive pulmonary disease, or COPD. By then, Croswell, a 76 ...

New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.